Sublingual Versus Intranasal Administration of Dexmedetomidine for Sedation of Children Undergoing Dental Treatment

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 27, 2019

Primary Completion Date

August 1, 2020

Study Completion Date

August 10, 2020

Conditions
Anti-anxiety AgentsModerate Sedation
Interventions
DRUG

Intranasal Dexmedetomidine

The mucosal atomizing device will be used intranasally where the sedative drug will be equally divided and sprayed into each nostril while the child semi reclined position.

DRUG

Sublingual Dexmedetomidine

The mucosal atomizing device will be used sublingually by asking the child to touch their maxillary incisor teeth with the tip of their tongue and instruct the child not to swallow the drug for 30 seconds.

Trial Locations (1)

21512

Faculty of Dentistry, Alexandria University, Alexandria

All Listed Sponsors
collaborator

Alexandria University

OTHER

lead

Nourhan M.Aly

OTHER

NCT04237532 - Sublingual Versus Intranasal Administration of Dexmedetomidine for Sedation of Children Undergoing Dental Treatment | Biotech Hunter | Biotech Hunter